Davide Iacuaniello

发表

Metabolic Alterations and Cardiovascular Outcomes of Cortisol Excess.

M. D. De Martino, G. Muscogiuri, C. Simeoli, 2016, Frontiers of hormone research.

Neuropsychiatric disorders in Cushing's syndrome

M. T. Pellecchia, M. D. De Martino, F. Iasevoli, 2015, Front. Neurosci..

The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center

R. Ferrigno, M. D. De Martino, A. Colao, 2019, Journal of endocrinological investigation.

Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study

A. Alibrandi, S. Cannavò, A. Colao, 2018, Endocrine.

Approach to patients with pseudo-Cushing’s states

A. Stigliano, C. Scaroni, A. Colao, 2019, Endocrine connections.

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”

G. Arnaldi, A. Colao, M. Boscaro, 2019, Endocrine.

The treatment with pasireotide in Cushing’s disease: effects of long-term treatment on tumor mass in the experience of a single center

C. Simeoli, C. Mainolfi, A. Colao, 2015, Endocrine.

Physiopathology, Diagnosis, and Treatment of Hypercortisolism

C. Simeoli, A. Colao, R. Pivonello, 2018 .

The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome

G. Arnaldi, V. Guarnotta, C. Simeoli, 2017, Endocrine.

Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI).

G. Castellini, M. den Heijer, A. Fisher, 2021, The journal of sexual medicine.